MX2022012671A - Vacuna terapeutica individualizada contra el cancer. - Google Patents

Vacuna terapeutica individualizada contra el cancer.

Info

Publication number
MX2022012671A
MX2022012671A MX2022012671A MX2022012671A MX2022012671A MX 2022012671 A MX2022012671 A MX 2022012671A MX 2022012671 A MX2022012671 A MX 2022012671A MX 2022012671 A MX2022012671 A MX 2022012671A MX 2022012671 A MX2022012671 A MX 2022012671A
Authority
MX
Mexico
Prior art keywords
anticancer vaccine
therapeutic anticancer
individualized therapeutic
vaccine
individualized
Prior art date
Application number
MX2022012671A
Other languages
English (en)
Spanish (es)
Inventor
Monika Sekelja
Agnete Brunsvik Fredriksen
Karoline Schjetne
Stine Granum
Original Assignee
Nykode Therapeutics ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nykode Therapeutics ASA filed Critical Nykode Therapeutics ASA
Publication of MX2022012671A publication Critical patent/MX2022012671A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022012671A 2020-04-09 2021-04-09 Vacuna terapeutica individualizada contra el cancer. MX2022012671A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA202070221 2020-04-09
DKPA202070338 2020-05-26
PCT/EP2021/059353 WO2021205027A1 (en) 2020-04-09 2021-04-09 Individualized therapeutic anticancer vaccine

Publications (1)

Publication Number Publication Date
MX2022012671A true MX2022012671A (es) 2023-01-05

Family

ID=75539309

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012671A MX2022012671A (es) 2020-04-09 2021-04-09 Vacuna terapeutica individualizada contra el cancer.

Country Status (11)

Country Link
US (1) US20230293650A1 (enExample)
EP (1) EP4132565A1 (enExample)
JP (1) JP2023522588A (enExample)
KR (1) KR20230004585A (enExample)
CN (1) CN115397462A (enExample)
AU (1) AU2021252155A1 (enExample)
BR (1) BR112022020277A2 (enExample)
CA (1) CA3172191A1 (enExample)
IL (1) IL297049A (enExample)
MX (1) MX2022012671A (enExample)
WO (1) WO2021205027A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3212592A1 (en) 2021-03-26 2022-09-29 Agnete Fredriksen Therapeutic combination for treating cancer
US20250339509A1 (en) 2021-05-03 2025-11-06 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
CA3216720A1 (en) 2021-05-10 2022-11-17 Agnete Brunsvik Fredriksen Co-expression of constructs and immunostimulatory compounds
WO2022238363A1 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
WO2022238381A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunotherapy constructs for treatment of disease
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use
WO2024100196A1 (en) 2022-11-09 2024-05-16 Nykode Therapeutics ASA Co-expression of constructs and polypeptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102057265B1 (ko) 2011-12-21 2019-12-18 백시바디 에이에스 Ｈｐｖ에 대한 백신들
EP2925348B1 (en) * 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
KR102833333B1 (ko) * 2016-01-08 2025-07-11 니코데 테라퓨틱스 에이에스에이 치료적 항암 네오에피토프 백신

Also Published As

Publication number Publication date
AU2021252155A1 (en) 2022-12-08
KR20230004585A (ko) 2023-01-06
EP4132565A1 (en) 2023-02-15
JP2023522588A (ja) 2023-05-31
CA3172191A1 (en) 2021-10-14
US20230293650A1 (en) 2023-09-21
CN115397462A (zh) 2022-11-25
BR112022020277A2 (pt) 2023-02-14
WO2021205027A1 (en) 2021-10-14
IL297049A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
MX2023008193A (es) Procedimientos para tratar el cáncer.
MX2023010429A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras).
SA519401435B1 (ar) مركبات حلقية ثنائية النيوكليوتيد
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
PH12019501959A1 (en) Therapeutic rna
MX2019001132A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
MX2023013912A (es) Metodos para inhibir ras.
SA519410320B1 (ar) مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل
MX2019010202A (es) Compuestos que interactuan con glicano y metodos de uso.
EA201291195A1 (ru) Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
AU2018256508A1 (en) Individualized vaccines for cancer
MX2018007844A (es) Derivado de benzopiperidina, metodo de preparacion del mismo y su uso medico del mismo.
PH12021553132A1 (en) Methods of using rad51 inhibitors for treatment of pancreatic cancer
WO2023107574A3 (en) Lipid-based compositions and methods thereof
MY196791A (en) New tetrahydropyrimidodiazepin and dihydropyridodiazepin compounds for treating pain and pain related conditions
MX2020012291A (es) Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario.
WO2019143883A3 (en) Compositions and methods for the treatment of cancer
ZA202403747B (en) Compounds and their uses as gpr183 inhibitors
EP4674415A3 (en) Azaquinolines as inhibitors of cd38
MY173104A (en) Compounds from antrodia camphorata, method for preparing the same and use thereof
MX2023006087A (es) Formulaciones liofilizadas de tegavivint.
EP4389146A3 (en) Tnf-a immunoconjugate therapy for the treatment of brain tumors
ZA202401405B (en) Compositions and methods for anti-pacap antibodies
MX2024005220A (es) Endoxifeno para el tratamiento del cancer.